Limited Stage Follicular Lymphoma: The Role of Radiation Therapy.

Filippi, Andrea Riccardo; Ciammella, Patrizia; Ricardi, Umberto

doi:10.4084/mjhid.2016.041

Cited by 12 publications

(7 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the patient’s young age and well-differentiated cellular morphology, local radiotherapy rather than systemic chemotherapy was chosen for adjuvant treatment. Adjuvant radiotherapy is considered as an effective adjuvant treatment strategy in early stage local lymphomas [10,12].…”

Section: Discussionmentioning

confidence: 99%

Pediatric follicular lymphoma of the parotid gland

Choi

Yim

et al. 2018

Arch Craniofac Surg

View full text Add to dashboard Cite

Primary malignant lymphoma rarely presents as a mass in the salivary gland. It accounts for about 1% of salivary gland tumors. The lymphomas of the parotid gland are mainly non-Hodgkin’s lymphoma of B-cell follicular type. It usually occurs in male adults and is very rare in children. In contrast to the intractable disease course of adult parotid follicular lymphoma, when occurred in children or adolescent, its prognosis is very good when it is first treated with surgical excision. Thus, a solitary follicular lymphoma in an extranodal site that has occurred in children is termed separately as pediatric follicular lymphoma (PFL). We share our treatment experience of a 16-year-old PFL patient through surgical removal combined with superficial parotidectomy. In line with the few previous case reports of PFL, we suggest that active surgical removal should be undertaken for solitary, extranodal follicular lymphoma of the pediatric and adolescent population.

show abstract

Section: Discussionmentioning

confidence: 99%

Pediatric follicular lymphoma of the parotid gland

Choi

Yim

et al. 2018

Arch Craniofac Surg

View full text Add to dashboard Cite

show abstract

“…The majority of patients with B-NHL were diagnosed at an advanced stage resulting in poor prognoses because of being asymptomatic at early stages of the disease ( 21 ). For example, 70–75% of patients with DLBCL were diagnosed at an advanced stage ( 22 ), and only 25% of patients with FL were diagnosed at early stage ( 23 ). The patients with aggressive B-NHL that were diagnosed at early stages of the disease not only had improved prognosis compared with patients diagnosed at an advanced stage (5-year overall survival, 90 vs. <70%) but also had advantages of reduced dosages, toxicities of therapy and less economic burden ( 24 – 26 ).…”

Section: Discussionmentioning

confidence: 99%

Volatile metabonomic profiling in urine to detect novel biomarkers for B‑cell non‑Hodgkin's lymphoma

Hua

Wang

Liu³

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

To date, there have been a limited number of useful biomarkers for the screening and monitoring of B-cell non-Hodgkin's lymphoma (B-NHL), which leads to the impetus to discover novel biomarkers for the disease. In the present study, gas chromatography-mass spectrometry (GC-MS) combined with head-space solid-phase micro-extraction (HS-SPME) was employed to analyze the volatile metabolites in the urine samples of 131 subjects. The subjects were divided into 4 main groups: Aggressive B-NHL, indolent B-NHL, benign lymphatic diseases patients and healthy volunteers. The differences of the concentrations of the potential biomarkers among the groups were assessed by non-parametric Wilcoxon's test. The ability of the potential biomarkers to discriminate between the four aforementioned groups was evaluated by receiver operating characteristic curves (ROC). The present study indicated that 4-heptanone, 2-methylpyrazine, 2-methylbutanal, 2,6-dimethyl-7-octen-2-ol and decanoic acid may serve as potential biomarkers for B-NHL. The area under the curve (AUC) values of single potential biomarker ranged from 0.634 to 0.901. The diagnostic models established with combined biomarkers exhibited higher diagnostic values (AUC, 0.824–0.968) compared with the models established with single biomarkers. The present study indicated that urinary volatile metabolites might be potential biomarkers for screening and monitoring of B-NHL.

show abstract

“…A c c e p t e d M a n u s c r i p t Abbreviations: IF (involved field); EF (extended field); TNI (total nodal irradiation); NS (not specified); CSS (cancer specific survival). Adapted by Filippi AR et al 14 A c c e p t e d M a n u s c r i p t…”

Section: Key Issuesmentioning

confidence: 99%

“…A c c e p t e d M a n u s c r i p t of FL according to WHO occur with a limited stage (Ann Arbor stages I and II) 13 at diagnosis. These cases are mainly approached with involved-field radiotherapy (IF-RT) 14 . The role of R consolidation is under evaluation (see below).…”

Section: Introductionmentioning

confidence: 99%

Current and future therapeutic approaches for the treatment of follicular lymphoma

Pulsoni

Cappelli

Ballotta

et al. 2018

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Recent advances in prognostication as well as management of Follicular Lymphoma (FL) are moving to personalized approach. Areas covered: Prognostic scores as well as consolidated and innovative therapeutic approaches are evaluated according to the various presentation modalities. For asymptomatic, low-tumor burden FL, a 'watch and wait' policy is currently the first-choice approach, although possible alternatives are discussed. Early stage FL may be treated with local radiotherapy although the role of minimal residual disease in possible additional agents should be determined. The first line treatment for symptomatic FL is chemo-immunotherapy followed by two years maintenance therapy with anti-CD20 monoclonal antibodies. A deeper knowledge of FL biology has opened new perspectives regarding the timing of therapy and has offered new targets for the development of novel agents that aim to change the therapeutic scenario of FL management. Expert commentary: The introduction of novel agents could question the incurability of FL and change the therapeutic goal from prolonging the complete remission state to eradicating the disease in young/fit patients, as well as improving quality of life in elderly/unfit patients. In the near future, combining new biologic agents and adoptive cell therapies could help in achieving these aims.

show abstract

Limited Stage Follicular Lymphoma: The Role of Radiation Therapy.

Cited by 12 publications

References 53 publications

Pediatric follicular lymphoma of the parotid gland

Pediatric follicular lymphoma of the parotid gland

Volatile metabonomic profiling in urine to detect novel biomarkers for B‑cell non‑Hodgkin's lymphoma

Current and future therapeutic approaches for the treatment of follicular lymphoma

Contact Info

Product

Resources

About